Literature DB >> 20385871

Heteroresistance of Cryptococcus gattii to fluconazole.

A Varma1, K J Kwon-Chung.   

Abstract

We analyzed 71 clinical and environmental Cryptococcus gattii strains that had been isolated before or after the advent of azole antifungals to determine their level of heteroresistance to fluconazole (LHF). All strains of C. gattii manifested heteroresistance, with LHFs that ranged between 4 microg/ml and 32 microg/ml. A considerably higher proportion of the C. gattii strains (86%) than Cryptococcus neoformans strains (46%) exhibited LHFs that were > or =16 microg/ml. No significant correlation was observed between the molecular type or serotypes of strains and their respective LHF. The strains which expressed a higher LHF were also more resistant to xenobiotics than the strains with a low LHF, and the level of resistance to xenobiotics was significantly higher than that reported for C. neoformans. The heteroresistant subpopulation, whose level of drug resistance had been raised in a stepwise manner to 64 microg/ml, reverted to the original LHF upon daily transfers in drug-free medium. Importantly, the strains with high LHFs were significantly more virulent than those with low LHFs. Since all the clinical isolates that had not been exposed to azole drugs as well as the environmental strains manifested heteroresistance to fluconazole, heteroresistance of C. gattii to azoles is an intrinsic mechanism as in C. neoformans and is associated with the strain's virulence.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20385871      PMCID: PMC2876399          DOI: 10.1128/AAC.00153-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  The hidden danger of primary fluconazole prophylaxis for patients with AIDS.

Authors:  J Berg; C J Clancy; M H Nguyen
Journal:  Clin Infect Dis       Date:  1998-01       Impact factor: 9.079

2.  Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis.

Authors:  A Armengou; C Porcar; J Mascaró; F García-Bragado
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

3.  Azole drug resistance as a cause of clinical relapse in AIDS patients with cryptococcal meningitis.

Authors:  H D Birley; E M Johnson; P McDonald; C Parry; P B Carey; D W Warnock
Journal:  Int J STD AIDS       Date:  1995 Sep-Oct       Impact factor: 1.359

4.  Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis.

Authors:  A Paugam; J Dupouy-Camet; P Blanche; J P Gangneux; C Tourte-Schaefer; D Sicard
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

5.  Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey.

Authors:  W Meyer; K Marszewska; M Amirmostofian; R P Igreja; C Hardtke; K Methling; M A Viviani; A Chindamporn; S Sukroongreung; M A John; D H Ellis; T C Sorrell
Journal:  Electrophoresis       Date:  1999-06       Impact factor: 3.535

6.  Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation.

Authors:  K A Marr; T C White; J A van Burik; R A Bowden
Journal:  Clin Infect Dis       Date:  1997-10       Impact factor: 9.079

7.  Fluconazole tolerance in clinical isolates of Cryptococcus neoformans.

Authors:  K Venkateswarlu; M Taylor; N J Manning; M G Rinaldi; S L Kelly
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

8.  Isolation of Cryptococcus neoformans var. gattii from Eucalyptus camaldulensis in India.

Authors:  A Chakrabarti; M Jatana; P Kumar; L Chatha; A Kaushal; A A Padhye
Journal:  J Clin Microbiol       Date:  1997-12       Impact factor: 5.948

Review 9.  Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome.

Authors:  D H Mitchell; T C Sorrell; A M Allworth; C H Heath; A R McGregor; K Papanaoum; M J Richards; T Gottlieb
Journal:  Clin Infect Dis       Date:  1995-03       Impact factor: 9.079

10.  Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR.

Authors:  K A Marr; C N Lyons; T R Rustad; R A Bowden; T C White; T Rustad
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

View more
  45 in total

1.  A case report of pulmonary cryptococcosis presenting as endobronchial obstruction.

Authors:  Qing Zhou; Bijie Hu; Changzhou Shao; Chunmei Zhou; Xing Zhang; Dong Yang; Chun Li
Journal:  J Thorac Dis       Date:  2013-08       Impact factor: 2.895

2.  In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations.

Authors:  Pilar Escribano; Sandra Recio; Teresa Peláez; Milagros González-Rivera; Emilio Bouza; Jesús Guinea
Journal:  Antimicrob Agents Chemother       Date:  2011-10-17       Impact factor: 5.191

3.  The production of reactive oxygen species is a universal action mechanism of Amphotericin B against pathogenic yeasts and contributes to the fungicidal effect of this drug.

Authors:  Ana Cecilia Mesa-Arango; Nuria Trevijano-Contador; Elvira Román; Ruth Sánchez-Fresneda; Celia Casas; Enrique Herrero; Juan Carlos Argüelles; Jesús Pla; Manuel Cuenca-Estrella; Oscar Zaragoza
Journal:  Antimicrob Agents Chemother       Date:  2014-08-25       Impact factor: 5.191

4.  Rare Cryptococus gattii infection in an immunocompetent dairy goat following a cesarean section.

Authors:  Aurora Villarroel; Tessa R Maggiulli
Journal:  Med Mycol Case Rep       Date:  2012-10-03

5.  Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment.

Authors:  Edward Sionov; Yun C Chang; Kyung J Kwon-Chung
Journal:  Antimicrob Agents Chemother       Date:  2013-07-08       Impact factor: 5.191

6.  Synthesis of a New Peptide-Coumarin Conjugate: A Potential Agent against Cryptococcosis.

Authors:  Soraya Z Ferreira; Hellem C Carneiro; Hugo A Lara; Rosemeire B Alves; Jarbas M Resende; Heloísa M Oliveira; Luciana M Silva; Daniel A Santos; Rossimiriam P Freitas
Journal:  ACS Med Chem Lett       Date:  2015-01-07       Impact factor: 4.345

7.  Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formation.

Authors:  Popchai Ngamskulrungroj; Yun Chang; Bryan Hansen; Cliff Bugge; Elizabeth Fischer; Kyung J Kwon-Chung
Journal:  FEMS Yeast Res       Date:  2012-07-18       Impact factor: 2.796

8.  Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil.

Authors:  P F Herkert; F Hagen; G L de Oliveira Salvador; R R Gomes; M S Ferreira; V A Vicente; M D Muro; R L Pinheiro; J F Meis; F Queiroz-Telles
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-01       Impact factor: 3.267

9.  A low-affinity penicillin-binding protein 2x variant is required for heteroresistance in Streptococcus pneumoniae.

Authors:  Hansjürg Engel; Moana Mika; Dalia Denapaite; Regine Hakenbeck; Kathrin Mühlemann; Manfred Heller; Lucy J Hathaway; Markus Hilty
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

10.  Roles of Three Cryptococcus neoformans and Cryptococcus gattii Efflux Pump-Coding Genes in Response to Drug Treatment.

Authors:  Miwha Chang; Edward Sionov; Ami Khanal Lamichhane; Kyung J Kwon-Chung; Yun C Chang
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.